B&D White Capital Company LLC Takes $417,000 Position in CVS Health Co. (NYSE:CVS)

B&D White Capital Company LLC acquired a new stake in CVS Health Co. (NYSE:CVS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 9,300 shares of the pharmacy operator's stock, valued at approximately $417,000.

A number of other institutional investors also recently made changes to their positions in the business. MidAtlantic Capital Management Inc. purchased a new stake in shares of CVS Health in the 3rd quarter worth about $25,000. Ridgewood Investments LLC increased its stake in shares of CVS Health by 255.7% in the 4th quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator's stock worth $28,000 after acquiring an additional 450 shares in the last quarter. Stonebridge Financial Group LLC bought a new position in shares of CVS Health in the 4th quarter worth about $28,000. Legacy Investment Solutions LLC bought a new position in shares of CVS Health in the 3rd quarter worth about $31,000. Finally, Reston Wealth Management LLC bought a new position in shares of CVS Health in the 3rd quarter worth about $32,000. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Stock Performance

Shares of NYSE CVS traded up $0.68 during trading on Thursday, reaching $64.54. 8,275,092 shares of the company traded hands, compared to its average volume of 12,605,323. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. The stock has a market capitalization of $81.37 billion, a PE ratio of 17.63, a P/E/G ratio of 0.98 and a beta of 0.61. The firm has a 50 day simple moving average of $53.48 and a 200-day simple moving average of $56.34. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $80.75.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. Equities research analysts anticipate that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Thursday, January 23rd were given a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 4.12%. The ex-dividend date was Thursday, January 23rd. CVS Health's dividend payout ratio is presently 72.68%.

Insider Buying and Selling

In other CVS Health news, Director Michael F. Mahoney purchased 30,000 shares of CVS Health stock in a transaction that occurred on Tuesday, February 18th. The shares were bought at an average price of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the transaction, the director now owns 39,356 shares of the company's stock, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.24% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages recently issued reports on CVS. Piper Sandler decreased their price target on shares of CVS Health from $72.00 to $64.00 and set an "overweight" rating for the company in a research note on Monday, November 25th. Cantor Fitzgerald upgraded shares of CVS Health from a "neutral" rating to an "overweight" rating in a research note on Wednesday, February 12th. UBS Group decreased their price target on shares of CVS Health from $62.00 to $59.00 and set a "neutral" rating for the company in a research note on Tuesday, February 11th. Deutsche Bank Aktiengesellschaft upgraded shares of CVS Health from a "hold" rating to a "buy" rating and set a $66.00 price objective for the company in a research note on Tuesday, December 3rd. Finally, Barclays raised their price objective on shares of CVS Health from $71.00 to $73.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, CVS Health presently has an average rating of "Moderate Buy" and a consensus target price of $70.00.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.